0844 GMT - Glanbia's third-quarter double-digit volume growth in optimum nutrition and Isopure products confirms brand strength and category health, Davy Research analyst Cathal Kenny says in a research note. The Irish nutrition group posted volume figures for the business that came ahead of Davy Research's forecast, Kenny says. As a result of the EPS guidance lift to the upper end of the range, Kenny says Davy Research will likely upgrade the company's full-year EPS estimate. Shares trade 4.9% higher at 15.11 euros. (nina.kienle@wsj.com)
(END) Dow Jones Newswires
November 05, 2025 03:44 ET (08:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.